Roche Weighs Pipeline Victories and Setbacks as H1 Report Nears
Published on 07/17/2026 at 18:33 | Redaktion boerse-global.de
Roche's drug development engine has delivered a sharply contrasting batch of clinical readouts just days before the Swiss pharma giant unveils its first-half results. The company scored a striking win in lung cancer and secured a second accelerated review from US regulators for its antibody Gazyva, yet was forced to pull the plug on a long-running Huntington's disease programme that failed to outperform placebo.
The most immediate catalyst centres on Gazyva (obinutuzumab), which has been granted a Priority Review by the US Food and Drug Administration for primary membranous nephropathy (pMN), a rare autoimmune kidney disease affecting the glomeruli. Left untreated, up to 30% of patients progress to kidney failure within a decade. The review relies on the Phase III MAJESTY study, which pitted Gazyva against the immunosuppressant tacrolimus: 36.9% of patients on Gazyva achieved complete remission at 104 weeks versus just 5.7% on tacrolimus — an adjusted difference of 31.1 percentage points. Secondary endpoints, including overall remission, also favoured the Roche drug, with no new safety signals emerging. This marks the second Priority Review for Gazyva in a matter of months — the FDA granted one in May for idiopathic nephrotic syndrome and awarded the compound Breakthrough Therapy designation for pMN as early as April. A regulatory decision is expected by November 2026. If approved, Gazyva would become the first FDA-cleared therapy for pMN, adding to its existing approvals for lupus nephritis and ongoing filings for lupus and idiopathic nephrotic syndrome.
On the oncology side, Roche's investigational KRAS G12C inhibitor Divarasib has delivered a notable head-to-head victory. In a Phase III study, it showed statistically significant superiority over already approved KRAS G12C inhibitors in non-small-cell lung cancer — a rare feat in oncology, where new agents typically aim against standard care rather than established targeted therapies. The strong data were disclosed via an ad-hoc announcement in early July. That bright spot, however, was tempered by the discontinuation of Tominersen, a Huntington's disease antisense oligonucleotide developed with Ionis Pharmaceuticals. A Phase II trial failed to demonstrate clinical superiority over placebo, ending a development programme that had consumed years of resources.
Should investors sell immediately? Or is it worth buying Roche?
Beyond these marquee programmes, Roche's pipeline continues to broaden. In haematology, the FDA accepted a supplemental application for the Lunsumio-Polivy combination in relapsed or refractory large B-cell lymphoma. The diagnostics division secured a CE mark for a new interferon-gamma release assay blood test for tuberculosis infections, designed to boost lab efficiency. And at the Alzheimer's Association International Conference, the company presented fresh data on blood-based diagnostic tests for early detection of amyloid pathology.
Analyst sentiment toward the stock remains mixed. Barclays Capital rates Roche "Overweight" with a price target of CHF 410, while JPMorgan Chase also recommends "Overweight" but sets a far lower target of CHF 325. The Deutsche Bank takes a more cautious stance with a "Hold" rating and a target of CHF 340. Over the past three months, the consensus has settled at "Hold," according to media reports. The shares have shown little directional movement: the last closing price was GBP 323.90, unchanged over both seven and thirty days, while the relative strength index of 47.2 points to neutral territory. The group's market capitalisation stands at roughly EUR 355.34 billion. In Swiss trading, the stock recently hovered around CHF 330.
Focus now shifts to July 23, when Roche will publish its half-year results ahead of the Zurich market open. In the first quarter, group revenue rose 6% on a currency-adjusted basis but fell 5% in nominal Swiss francs, reflecting the strong franc's year-on-year appreciation. Investors will be watching whether that headwind persists and whether the pharmaceutical division's margin performance can sustain the growth narrative that the pipeline's latest wins are meant to support.
Ad
Roche Stock: New Analysis - 17 July
Fresh Roche information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
